Qiagen (QGEN) Tops Q3 EPS by 8c

Go back to Qiagen (QGEN) Tops Q3 EPS by 8c

QIAGEN Exceeds Outlook for Q3 2022 with 18% CER Sales Growth in Non-COVID Product Portfolio and Raises Full-Year 2022 Outlook

November 7, 2022 4:05 PM EST

Q3 2022: Net sales of $500 million (-7% at actual rates, 0% at constant exchange rates, CER); diluted EPS of $0.36 and adjusted diluted EPS of $0.53 Net sales at CER of $533 million vs. outlook for at least $510 million CER, adjusted diluted EPS of $0.55 CER vs. outlook for at least $0.48 CER 18% CER growth in non-COVID product portfolio to $417 million First nine months 2022 operating cash flow up 34% to $591 million, while free cash flow advances 67% to $504 million on strong business expansion 2022 sales outlook raised to about $2.25 billion CER, reaffirmed double-digit... More